A detailed history of Cwa Asset Management Group, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Cwa Asset Management Group, LLC holds 49,000 shares of AKBA stock, worth $90,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,000
Previous 49,000 -0.0%
Holding current value
$90,160
Previous $89,000 28.09%
% of portfolio
0.0%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

BUY
$0.51 - $1.43 $10,200 - $28,600
20,000 Added 68.97%
49,000 $45,000
Q2 2022

Jul 21, 2022

BUY
$0.32 - $0.67 $9,280 - $19,430
29,000 New
29,000 $10,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $338M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Cwa Asset Management Group, LLC Portfolio

Follow Cwa Asset Management Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwa Asset Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwa Asset Management Group, LLC with notifications on news.